AK006
Based on 1 Customer Validation
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research.
For research use only. We do not sell to patients.
- Purity: 98.78%
- Molecular Weight:143.91 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
Siglec-6
AK006 can extensively inhibit both IgE-dependent and non-IgE-dependent activation and degranulation of mast cells, covering various signaling pathways including FcεRI, complement component C5a receptor, and MRGPRX2[1][2].
AK006,
compared with another inhibitory antibody Lirentelimab (HY-P99371) (targeting Siglec-8), demonstrates a stronger ability to inhibit mast cell degranulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
O43699
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 143.91 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Poto R, et al. Human Lung Mast Cells: Therapeutic Implications in Asthma. Int J Mol Sci. 2022 Nov 21;23(22):14466. [Content Brief]
[2]. Metz M, et al. Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy. 2024 Jan;79(1):37-51. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)